On May 4, 2020, Stemline Therapeutics, Inc. entered into an Agreement and Plan of Merger with Berlin-Chemie AG and Mercury Merger Sub, Inc. Pursuant to the Merger Agreement, as of the Effective Time, Ron Bentsur, Ivan Bergstein, Darren Cline, Alan Forman, Daniel Hume, Mark Sard and Kenneth Zuerblis each resigned as a director of Stemline. These resignations were not a result of any disagreement between Stemline and the directors on any matter relating to Stemline's operations, policies or practices.